[{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Antares Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Antares Pharma"},{"orgOrder":0,"company":"Serenity LLC","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved","graph3":"Serenity LLC","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"","sponsorNew":"Serenity LLC \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serenity LLC \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Serenity Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved","graph3":"Serenity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Desmopressin Acetate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Desmopressin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The company launched desmopressin acetate for injection in the US as a therapeutic equivalent generic for DDAVP, indicated for central diabetes insipidus, hemophilia A.

                          Brand Name : DDAVP-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 15, 2024

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Serenity Pharmaceuticals

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Serenity Pharmaceuticals

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.

                          Brand Name : Noctiva

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          March 09, 2022

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Urology

                          Highest Development Status : Approved

                          Sponsor : Acerus Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Serenity LLC

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Serenity LLC

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.

                          Brand Name : Noctiva

                          Molecule Type : Peptide

                          Upfront Cash : $6.0 million

                          February 28, 2022

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Urology

                          Highest Development Status : Approved

                          Sponsor : Acerus Pharmaceuticals

                          Deal Size : $16.0 million

                          Deal Type : Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.

                          Brand Name : Nocdurna

                          Molecule Type : Large molecule

                          Upfront Cash : $5.0 million

                          October 01, 2020

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Urology

                          Highest Development Status : Approved

                          Sponsor : Antares Pharma

                          Deal Size : $25.0 million

                          Deal Type : Licensing Agreement

                          blank